Analyst Price Targets — TYRA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 14, 2026 8:14 pm | Brad Canino | Guggenheim | $54.00 | $35.27 | TheFly | Tyra Biosciences initiated with a Buy at Guggenheim |
| February 17, 2026 11:12 am | Mitchell Kapoor | H.C. Wainwright | $45.00 | $27.99 | TheFly | Tyra Biosciences price target raised to $45 from $30 at H.C. Wainwright |
| February 13, 2026 2:03 pm | Robert Driscoll | Wedbush | $53.00 | $30.10 | TheFly | Tyra Biosciences price target raised to $53 from $37 at Wedbush |
| February 3, 2026 1:04 pm | — | Oppenheimer | $50.00 | $31.72 | TheFly | Tyra Biosciences price target raised to $50 from $36 at Oppenheimer |
| January 27, 2026 9:30 pm | — | Barclays | $59.00 | $31.40 | TheFly | Tyra Biosciences initiated with an Overweight at Barclays |
| January 23, 2026 11:59 am | — | Piper Sandler | $42.00 | $30.91 | TheFly | Tyra Biosciences price target raised to $42 from $33 at Piper Sandler |
| December 16, 2025 11:20 am | Robert Driscoll | Wedbush | $37.00 | $22.11 | TheFly | Wedbush raises price target on Tyra Biosciences, adds to Best Ideas List |
| September 10, 2025 11:03 am | Matthew Biegler | Oppenheimer | $36.00 | $12.18 | TheFly | Tyra Biosciences price target raised to $36 from $30 at Oppenheimer |
| November 11, 2024 12:23 pm | Mitchell Kapoor | H.C. Wainwright | $30.00 | $16.70 | StreetInsider | Tyra Biosciences (TYRA) PT Lowered to $30 at H.C. Wainwright |
| October 18, 2024 6:06 am | Jason Zemansky | Bank of America Securities | $31.00 | $25.98 | StreetInsider | BofA Securities Upgrades Tyra Biosciences (TYRA) to Buy |
Latest News for TYRA
-Collaboration aims to raise awareness of UTUC and the need for continued innovation for patients living with this rare and difficult-to-treat cancer- CARLSBAD, Calif., May 21, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology,…
Tyra Biosciences develops targeted therapies for cancer and rare diseases, leveraging proprietary technology to advance its drug pipeline.
Tyra Biosciences, Inc. (TYRA) Presents at Bank of America Global Healthcare Conference 2026 Transcript
- Advanced "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH - - First LG-UTUC patient dosed with dabogratinib in SURF303; initial results expected in 2027 - - Initial Ph2 data readout from SURF302 expected in August 2026 (n>20 enrolled to date) - - Initial Ph2 data readout from safety sentinel cohort in BEACH301 expected in Q4 2026 (4th dose level cleared) - - Cash,…
CARLSBAD, Calif., May 7, 2026 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced participation at the following investor conferences: BofA Securities Health Care Conference 2026 Format: Virtual fireside chat and…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for TYRA.
U.S. House Trading
No House trades found for TYRA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.